-
-
-
-
-
-
-
Barclays Upgrades Quest Diagnostics (DGX) to Overweight
-
-
-
-
-
-
-
Quest Diagnostics wins FDA breakthrough status for cancer test
-
-
-
-
-
-
-
Quest Diagnostics (DGX) Tops Q1 EPS by 5c; offers guidance
-
-
-
-
-
-
-
Quest Diagnostics (DGX) PT Raised to $180 at JPMorgan
-
-
-
-
-
-
-
Mainz Biomed (MYNZ) Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
-
-
-
-
-
-
-
CFRA Upgrades Quest Diagnostics (DGX) to Buy
-
-
-
-
-
-
-
Quest Diagnostics (DGX) Declares $0.75 Quarterly Dividend; 2% Yield
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

